Tilray Brands (TLRY) Stock Overview
A lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
TLRY Community Fair Values
Create NarrativeSee what 177 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Tilray Brands, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.14 |
| 52 Week High | US$23.20 |
| 52 Week Low | US$3.67 |
| Beta | 1.92 |
| 1 Month Change | -11.35% |
| 3 Month Change | -15.16% |
| 1 Year Change | -64.92% |
| 3 Year Change | -83.83% |
| 5 Year Change | -96.31% |
| Change since IPO | -97.43% |
Recent News & Updates
Seeking Alpha • Sep 11
Tilray: Schedule III Is Moving Forward, And The Stock Is Still Cheap
Summary Tilray Brands, Inc. remains a Buy as international medical cannabis revenue grew 34% and regulatory progress in the U.S. has advanced. TLRY’s international cannabis business is now the primary growth driver, with strong gains in Germany, UK, Poland, and Italy despite price compression. GAAP profitability and free cash flow are still lacking, and dilution remains a concern, but underlying cash generation is improving. At 0.65x forward EV/sales, TLRY stock’s valuation reflects deep market skepticism despite improved balance sheet and regulatory tailwinds. Read the full article on Seeking Alpha
Narrative Update • Aug 27
TLRY: Medical Platform And International Delays Will Shape Future Cash Flow Visibility
Analysts have trimmed their price target on Tilray Brands to $4.25 from $5.00. The revised target reflects updated assumptions for slower revenue growth, a modestly higher discount rate, and slightly stronger profit margin expectations following recent commentary on permit delays in international cannabis sales and more cautious views on beverage demand.
Narrative Update • Aug 12
TLRY: New Beverage And Medical Expansion Will Drive Future Upside Potential
Analysts have trimmed their average price target on Tilray Brands. Recent estimates have moved from around $10.04 to about $7.84, citing lower modeled revenue growth, a slightly higher discount rate, and updates to sales expectations, including a cut to a $5 target from $7, along with more cautious views on international cannabis permits and beverage demand.
Narrative Update • Jul 29
TLRY: Beverage And Medical Expansion Will Drive Long Term Cash Flow
Analysts have reduced their fair value estimate for Tilray Brands, cutting the price target by about $3 after revising assumptions for revenue growth, profit margins and future P/E in light of more cautious expectations for international cannabis permits and beverage sales. What's in the News for Tilray Brands Tilray Medical launched its first medical cannabis product in Panama, Tilray Oral Solution CBD100, manufactured at its EU-GMP certified facility in Portugal and distributed through Farmacias Arrocha under medical prescription.Recent updates
Seeking Alpha • Sep 11
Tilray: Schedule III Is Moving Forward, And The Stock Is Still Cheap
Summary Tilray Brands, Inc. remains a Buy as international medical cannabis revenue grew 34% and regulatory progress in the U.S. has advanced. TLRY’s international cannabis business is now the primary growth driver, with strong gains in Germany, UK, Poland, and Italy despite price compression. GAAP profitability and free cash flow are still lacking, and dilution remains a concern, but underlying cash generation is improving. At 0.65x forward EV/sales, TLRY stock’s valuation reflects deep market skepticism despite improved balance sheet and regulatory tailwinds. Read the full article on Seeking AlphaNarrative Update • Aug 27
TLRY: Medical Platform And International Delays Will Shape Future Cash Flow Visibility
Analysts have trimmed their price target on Tilray Brands to $4.25 from $5.00. The revised target reflects updated assumptions for slower revenue growth, a modestly higher discount rate, and slightly stronger profit margin expectations following recent commentary on permit delays in international cannabis sales and more cautious views on beverage demand.Narrative Update • Aug 12
TLRY: New Beverage And Medical Expansion Will Drive Future Upside Potential
Analysts have trimmed their average price target on Tilray Brands. Recent estimates have moved from around $10.04 to about $7.84, citing lower modeled revenue growth, a slightly higher discount rate, and updates to sales expectations, including a cut to a $5 target from $7, along with more cautious views on international cannabis permits and beverage demand.Narrative Update • Jul 29
TLRY: Beverage And Medical Expansion Will Drive Long Term Cash Flow
Analysts have reduced their fair value estimate for Tilray Brands, cutting the price target by about $3 after revising assumptions for revenue growth, profit margins and future P/E in light of more cautious expectations for international cannabis permits and beverage sales. What's in the News for Tilray Brands Tilray Medical launched its first medical cannabis product in Panama, Tilray Oral Solution CBD100, manufactured at its EU-GMP certified facility in Portugal and distributed through Farmacias Arrocha under medical prescription.Narrative Update • Jul 14
TLRY: Partial Rescheduling And Medical Assets Will Support Future Cash Flow Visibility
Analysts have trimmed their 12 month price target for Tilray Brands to $5.00 from $6.50, citing updated expectations for slower revenue growth, slightly lower profit margins, and a reduced future P/E multiple following recent adjustments to sales forecasts and cannabis permit timing. Analyst Commentary Recent research updates on Tilray Brands highlight a more cautious tone, with several bearish analysts revisiting their revenue assumptions, margin outlook, and valuation frameworks in light of revised sales expectations and cannabis permit timing.Narrative Update • Jun 24
TLRY: Partial Cannabis Rescheduling And Beverage Partnerships Will Improve Future Cash Flow Visibility
Analysts recently trimmed their average 12 month price target for Tilray Brands to about $6.50 from roughly $9.00. This reflects updated assumptions for slower revenue growth, slightly lower profit margins, a higher discount rate and a reduced future P/E multiple, even as some research cites potential benefits from partial cannabis re scheduling.Narrative Update • Jun 06
TLRY: Cannabis Rescheduling And Margin Outlook Will Drive Future Upside Potential
Tilray Brands' consensus analyst price target has been reset lower by roughly $2 to $3 per share as analysts factor in updated cannabis re-scheduling expectations and revised profit margin and future P/E assumptions following recent firm-level target cuts and one upgrade. Analyst Commentary Recent Street research on Tilray Brands shows a mix of optimism around potential regulatory shifts and caution around profit expectations and valuation multiples.Narrative Update • May 17
TLRY: BrewDog Deal And Cannabis Rescheduling Will Shape Future Upside Potential
Analysts have trimmed their average price target on Tilray Brands by a few dollars to reflect updated assumptions around discount rates, profit margins and future P/E multiples, even as some highlight potential benefits from partial cannabis rescheduling and recent acquisitions. Analyst Commentary Bullish Takeaways Bullish analysts view the partial cannabis rescheduling order as extremely favorable, seeing scope for improved sector sentiment and potential support for valuation multiples if regulatory risk is perceived as lower.Narrative Update • May 02
TLRY: BrewDog Acquisition And Cannabis Rescheduling Will Drive Future Upside
Analysts have cut their average price target on Tilray Brands to about $10.04 from $16.17, reflecting updated assumptions on discount rates, revenue growth, profit margins, and a reset future P/E following recent research that includes target reductions tied to the BrewDog asset acquisition and evolving views on potential U.S. cannabis rescheduling. Analyst Commentary Recent research on Tilray Brands highlights a mix of optimism around regulatory developments and caution around execution risks, especially following the BrewDog asset acquisition and a series of price target resets.Narrative Update • Apr 18
TLRY: BrewDog Integration And Synergies Will Support Long Term Cash Flow Potential
The analyst price target for Tilray Brands has been reduced by several dollars to $9.00. This reflects analysts' focus on lower future P/E assumptions and execution risks around recent acquisitions, even as they factor in slightly higher revenue growth and profit margin estimates.Narrative Update • Apr 04
TLRY: BrewDog Acquisition Execution Will Support Long Term Cash Flow Visibility
Tilray Brands' updated analyst price target framework now points to an implied fair value shift from $19.22 to $20.25. Analysts cite changes to revenue growth assumptions, profit margin expectations, and a higher future P/E multiple following a mix of price target cuts and a recent upgrade on the stock.Narrative Update • Mar 20
TLRY: BrewDog Acquisition Synergies And Schedule III Shift Will Improve Cash Flow Visibility
Analysts have reduced their Tilray Brands price targets to $9.00 from $10.00, reflecting caution regarding the BrewDog asset acquisition and a focus on the company demonstrating it can achieve operational synergies, as well as provide clearer long term visibility into sales and cash flows. Analyst Commentary Recent research updates point to a cautious stance on Tilray Brands, with several Bearish analysts trimming price targets and reiterating more neutral views after both the BrewDog asset acquisition and the latest quarterly results.Narrative Update • Mar 05
TLRY: Schedule III Shift And Medical Push Will Improve Cash Flow Visibility
Narrative Update on Tilray Brands The analyst price target for Tilray Brands has been trimmed from $9.25 to $9.00 as analysts factor in a slightly higher discount rate, a lower assumed future P/E, and execution risks and synergy uncertainty around the BrewDog asset acquisition, even though revenue growth and profit margin assumptions remain modestly higher. Analyst Commentary Recent Street research on Tilray Brands has leaned cautious, with multiple bearish analysts trimming price targets and maintaining neutral stances despite some operational positives.Narrative Update • Feb 19
TLRY: Rescheduling And Licensing Agreements Will Support Long Term Cash Flow Visibility
Analysts have updated their price target on Tilray Brands to $19.22 from $1.83, reflecting revised assumptions around revenue growth, profit margins, and future P/E following recent coverage initiations and target resets that cited solid Q2 sales with mixed visibility on long-term sales and cash flow. Analyst Commentary Recent Street commentary around Tilray Brands has been mixed, with some firms trimming price targets while keeping ratings neutral.Narrative Update • Feb 05
TLRY: Schedule III Rescheduling And Medical Expansion Will Support Cash Flow Visibility
Analysts have trimmed their price targets on Tilray Brands to around $10, reflecting a more cautious stance after recent quarterly results that they viewed as generally in line. Solid international and distribution sales were partly offset by ongoing questions around long term sales visibility and cash flow.Narrative Update • Jan 21
TLRY: Schedule III Shift Will Test Medical Expansion And Cash Flow Visibility
Analysts have adjusted their fair value estimate for Tilray Brands from $8.50 to $9.25, citing recent target revisions that reflect more cautious revenue growth assumptions, steady profitability expectations, and an updated outlook for the future price-to-earnings ratio. Analyst Commentary Recent Street research has leaned cautious on Tilray Brands, with bearish analysts trimming price targets and flagging risks around visibility into the company’s longer term financial profile.Analysis Article • Jan 16
Lacklustre Performance Is Driving Tilray Brands, Inc.'s (NASDAQ:TLRY) 30% Price Drop
To the annoyance of some shareholders, Tilray Brands, Inc. ( NASDAQ:TLRY ) shares are down a considerable 30% in the...Narrative Update • Jan 06
TLRY: Rescheduling To Schedule III Will Expose Medical Expansion Hurdles
Analysts have lifted their fair value estimate for Tilray Brands to $8.50 from $0.60, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E that they see as better reflecting the company’s current risk and earnings profile. What's in the News President Trump signed an executive order directing Attorney General Pam Bondi to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act.Narrative Update • Dec 20
TLRY: Reverse Split Will Drive Future Upside As Medical Expansion Advances
Analysts have modestly raised their price target on Tilray Brands to reflect slightly stronger long term revenue growth expectations, even as they factor in significantly compressed profit margins and a sharply higher assumed future price to earnings multiple. What's in the News Tilray Medical outlined a strategic framework for U.S. medical cannabis expansion following federal rescheduling, creating Tilray Medical USA Inc.Narrative Update • Dec 06
TLRY: Reverse Split And Medical Expansion Will Drive Future Upside
Analysts have significantly raised their price target on Tilray Brands, lifting fair value expectations from approximately $1.78 to $16.17 per share, citing improved long term earnings visibility and a more favorable valuation multiple outlook. What's in the News Announced a 1 for 10 reverse stock split effective December 2, 2025, aiming to support continued Nasdaq listing and broaden institutional investor eligibility (company announcement).Analysis Article • Nov 24
Tilray Brands, Inc. (NASDAQ:TLRY) Looks Inexpensive After Falling 39% But Perhaps Not Attractive Enough
The Tilray Brands, Inc. ( NASDAQ:TLRY ) share price has fared very poorly over the last month, falling by a substantial...Narrative Update • Nov 22
TLRY: Federal Policy Shifts Will Drive New U.S. Cannabis Opportunities
Analysts have raised Tilray Brands' price target from $1.50 to $2.00, citing strengthened expectations due to shifting U.S. federal policy toward cannabis and the company's strong market position. Analyst Commentary Analysts have highlighted a range of factors that support an optimistic outlook for Tilray Brands, while also noting certain risks that could affect the company's future performance.Narrative Update • Nov 07
TLRY: Progress On U.S. Rescheduling Will Unlock New Market Access
Tilray Brands has received an increased analyst price target from $1.50 to $2.00 per share, reflecting greater optimism because of anticipated regulatory changes and the company’s strong industry positioning. Analyst Commentary Bullish analysts have reacted positively to recent developments affecting Tilray Brands, noting a number of factors that could drive further growth and improve the company’s outlook.Narrative Update • Oct 23
Upcoming Federal Policy Shifts Will Open New Opportunities In Cannabis Markets
Analysts have raised their price target on Tilray Brands from $1.50 to $2.00, citing recent shifts in U.S. federal policy toward cannabis and the company's strong positioning to benefit from potential market expansion. Analyst Commentary Following the price target increase, analysts have shared both optimistic and cautious perspectives on Tilray Brands, reflecting on the company's future prospects and potential risks.Narrative Update • Oct 09
Expanding European Cannabis Markets Will Unlock Global Wellness Potential
Analysts have raised their price target for Tilray Brands from $1.50 to $2.00, citing anticipated progress in U.S. cannabis policy and Tilray's strong positioning to benefit from broader market access. Analyst Commentary Recent commentary from bullish analysts highlights both the strengths and potential hurdles facing Tilray Brands in the evolving cannabis market.Analysis Article • Oct 03
Tilray Brands, Inc.'s (NASDAQ:TLRY) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Tilray Brands, Inc. ( NASDAQ:TLRY ) shares have continued their recent momentum with a 29% gain in the last month...Narrative Update • Aug 26
Expanding European Cannabis Markets Will Unlock Global Wellness Potential
Tilray Brands’ consensus price target has increased to $0.983 as analysts cite improved U.S. political momentum toward cannabis rescheduling and Tilray’s strong positioning to benefit from expanding market opportunities. Analyst Commentary Positive political developments, with momentum towards rescheduling marijuana from Schedule I to Schedule III in the U.S., indicating a potential shift in federal cannabis policy.Analysis Article • Aug 18
Tilray Brands, Inc. (NASDAQ:TLRY) Surges 66% Yet Its Low P/S Is No Reason For Excitement
Despite an already strong run, Tilray Brands, Inc. ( NASDAQ:TLRY ) shares have been powering on, with a gain of 66% in...Analysis Article • Jul 04
Tilray Brands, Inc. (NASDAQ:TLRY) Shares Fly 35% But Investors Aren't Buying For Growth
Tilray Brands, Inc. ( NASDAQ:TLRY ) shareholders are no doubt pleased to see that the share price has bounced 35% in...Shareholder Returns
| TLRY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.0% | -2.3% | -1.5% |
| 1Y | -64.9% | 47.5% | 13.3% |
Return vs Industry: TLRY underperformed the US Pharmaceuticals industry which returned 47.5% over the past year.
Return vs Market: TLRY underperformed the US Market which returned 13.3% over the past year.
Price Volatility
| TLRY volatility | |
|---|---|
| TLRY Average Weekly Movement | 6.7% |
| Pharmaceuticals Industry Average Movement | 8.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: TLRY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TLRY's weekly volatility has decreased from 15% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 3,595 | Irwin Simon | www.tilray.com |
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; resells and distributes pharmaceutical and wellness products; and produces, markets, and sells beverage products, and hemp-based food products.
Tilray Brands, Inc. Fundamentals Summary
| TLRY fundamental statistics | |
|---|---|
| Market cap | US$550.71m |
| Earnings (TTM) | -US$121.40m |
| Revenue (TTM) | US$915.45m |
0.6x
P/S Ratio-4.7x
P/E RatioIs TLRY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLRY income statement (TTM) | |
|---|---|
| Revenue | US$915.45m |
| Cost of Revenue | US$652.86m |
| Gross Profit | US$262.59m |
| Other Expenses | US$383.99m |
| Earnings | -US$121.40m |
Last Reported Earnings
May 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.89 |
| Gross Margin | 28.68% |
| Net Profit Margin | -13.26% |
| Debt/Equity Ratio | 14.2% |
How did TLRY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 06:58 |
| End of Day Share Price | 2026/09/14 00:00 |
| Earnings | 2026/05/31 |
| Annual Earnings | 2026/05/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tilray Brands, Inc. is covered by 27 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Jesse Pytlak | ATB Cormark Historical (Cormark Securities) |